Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy ... the loss of photoreceptors and retinal pigment epithelial (RPE) cells, the central ...

Zanzottera EC, Ach T, Huisingh C, Messinger JD, Spaide RF, Curcio CA: Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy in age-related macular degeneration.

However, GA involves more significant and irreversible loss of retinal tissue. Therefore, the difference between geographic atrophy and dry AMD lies in the severity and stage of the condition.

Geographic atrophy is an advanced form of dry age-related macular degeneration that causes vision loss in older adults. Until recently, there were no treatments available to target the root cause.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

It may show areas of loss of outer retinal layers and the collapse of overlying layers in the region of the geographic atrophy. These often show an increased reflectance of the underlying ...

The phase 1b trial will enrol patients with geographic ... geographic atrophy – an advanced form of the disease characterised by the loss of photoreceptors and retinal pigment epithelial ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary ... and management of retinal vein occlusion.

and preserving the integrity of the retinal pigment epithelium, with the potential of preventing retinal degeneration and vision loss. Judith Greciet, CEO of PulseSight Therapeutics, said ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.